JW Pharma takes gout drug Epaminurad to Malaysia for phase 3

In addition to the phase 3 trial, the S.Korean drug maker also pursues global technology licensing of Epaminurad

JW Pharma takes gout drug Epaminurad to Malaysia for phase 3
Ji-Hyun Lee 1
2024-01-15 13:12:41 bluesky@hankyung.com
Bio & Pharma


South Korea's JW Pharmaceutical Corp., announced on Monday that it has received approval from the Malaysian National Pharmaceutical Regulatory Agency (NPRA) for a phase 3 clinical trial of its gout treatment drug, Epaminurad (URC102).

This approval makes Malaysia the fifth Asian country, after South Korea, Taiwan, Thailand and Singapore, to approve a phase 3 clinical trial of Epaminurad.

The phase 3 trial will evaluate the efficacy and safety of Epaminurad versus the comparator drug, febuxostat, in 588 gout patients in the participating countries.

Epaminurad, which is being developed as an oral medication, works by selectively inhibiting the urate transporter, human uric acid transporter-1 (hURAT1), to promote urate excretion, the company explained.

It is effective for hyperuricemia, a condition in which the blood uric acid level is abnormally high, and gout.

In addition to the phase 3 trial, JW Pharmaceutical is also pursuing global technology licensing of Epaminurad.

In 2019, the company licensed the development and marketing rights of Epaminurad in China, Hong Kong, and Macau to Simcere Pharmaceutical in China.

Write to Ji-Hyun Lee at bluesky@hankyung.com
##JW Pharmaceutical epaminurad URC102 phase 3 trial approval Malaysia #jw pharma epaminurad #epaminurad malaysia #korea jw pharma

JW Pharma to conduct Phase 3 trials in Thailand for gout treatment

JW Pharma to conduct Phase 3 trials in Thailand for gout treatment

The headquarters of JW Pharmaceutical in Gwacheon South Korea's JW Pharmaceutical Corp. on Thursday said it received approval from Thailand's Food and Drug Administration to conduct Phase 3 clinical trials for the company's gout candidate drug Epaminurad (URC102).This is the second internationa

JW Pharma to participate in S.Korea’s new drug project

JW Pharma to participate in S.Korea’s new drug project

South Korea's JW Pharmaceutical announced on Monday that its experimental hair loss drug, JW0061, has been selected for a two-year funding program by the Korea Drug Development Fund (KDDF), the country's premier public funder of pharmaceutical research and development.JW0061, described as a gr

JW Pharma gets OK for phase 3 clinical trials of URC102 in Taiwan

JW Pharma gets OK for phase 3 clinical trials of URC102 in Taiwan

The headquarters of JW Pharmaceutical in Gwacheon South Korea's JW Pharmaceutical has won approval from Taiwan's Food and Drug Administration (TFDA) to conduct phase 3 clinical trials for its gout treatment, Epaminurad (URC102), the company said on Friday.Epaminurad, an oral uric acid transport
(* comment hide *}